Anavex life sciences to present at the 11th annual svb leerink global healthcare conference

New york, feb. 10, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will participate in the virtual 11th annual svb leerink global healthcare conference and present on wednesday, february 16 at 3 pm et.
AVXL Ratings Summary
AVXL Quant Ranking